BGB-B167 / BeiGene  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BGB-B167 / BeiGene
NCT05494762: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Active, not recruiting
1
55
US, RoW
BGB-B167, Tislelizumab, BGB-A317
BeiGene
Solid Tumor
01/25
01/25
NCT05644626: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Withdrawn
1
254
NA
BGB-B167, Tislelizumab, BGB-A317
BeiGene
Solid Tumors
03/25
08/25

Download Options